Industry Overview

Global omics-based clinical trials market was valued at USD 27.5 Bn in 2021 and is expected to grow at a CAGR of 7.6% during 2022 – 2032.

Introduction

The omics-based clinical trials market Intelligence & research report cover in-depth analysis of the omics-based clinical trials industry with a key focus on the global market trends, growth opportunities, market size (2021), market forecast (2022-2032), key players Investment analysis by countries, significant industry development, etc. The report aims to provide an overview of the global omics-based clinical trials market with detailed market division by phase, by study design, by indication, and by regions. The omics-based clinical trials market is projected to registered significant growth in specific profiled segments while other market segments are expected to witnessed declined in the revenue share over the forecasted period accounted for several influencing factors which are included in the report. The report provides industry status of the omics-based clinical trials market players with market share, SWOT analysis, porter’s five force analysis, financial analysis & business strategy. The report focusses on providing data on growth opportunities, investment pockets, and regional analysis to leverage industry opportunities and gain competitive edge in the omics-based clinical trials market.

Omics-Based Clinical Trials Market Covid-19 Pandemic Impact & Recovery Analysis

The report focusses extensively on covid-19 pandemic impact on omics-based clinical trials market across the globe. Major industry players implemented various business strategies to recover from this global challenge which are analyze in the report. COVID-19 pandemic short -term and long-term effects on omics-based clinical trials market are provided in the report.

Leading companies in the omics-based clinical trials market are expected to implement key business strategies along with portfolio diversification to gain competitive edge in the market. Business strategy with pre and post covid-analysis by key competitors is provided in detail in the competitive landscape mapping segment of the omics-based clinical trials market report.

Omics-Based Clinical Trials Market Segment Analysis

The report bifurcated omics-based clinical trials market into key segments such as by phase, by study design, by indication, and by regions, which represents global market. Market vendors across the globe in North America, Europe, Asia Pacific, Middle East & Africa, and South America are included in the report. Major factors that influence market growth in specific segment are analyze on Micro and Macro level.  The report also outlines some of the biggest development opportunities, market prediction, the introduction of the new products, and forecasting, numerous economic factors that are key in deciding the omics-based clinical trials market pattern, market attractiveness and buying decisions.

Omics-Based Clinical Trials Market Regional Analysis

On the basis of region, the market is segmented into North America, Europe, Asia Pacific, Middle East & Africa and South America. Country level analysis for each region is conducted to determine leading market region and identify future growth opportunities in various regions.

Competitive Insights

Companies in the omics-based clinical trials market are bifurcated into leading, emerging and prominent players for competitive landscape mapping. Prominent players in the omics-based clinical trials market are investing heavily in the mergers, acquisition, partnerships and research & development of the innovative products to gain larger market share.

Key market players (Direct & Indirect Competitors)

• SGS SA
• Eli Lilly and Company
• Pfizer Inc.
• Covance Inc.
• Novo Nordisk
• Rebus Bio
• Parexel International Corporation
• Pharmaceutical Product Development (PPD)
• Charles River Laboratory
• ICON plc
• Others

Omics-Based Clinical Trials Market Segmentation

The market intelligence & research report categorizes the omics-based clinical trials market to forecast the revenues and analyze trends in each of the following subsegments:

• By Phase (Revenue, USD Million, 2017 – 2032)
  • Phase I
  • Phase II
  • Phase III
  • Phase IV
• By Study Design (Revenue, USD Million, 2017 – 2032)
  • Expanded Access Studies
  • Interventional Studies
  • Observational Studies
• By Indication (Revenue, USD Million, 2017 – 2032)
  • Oncology
  • Cardiology
  • CNS Diseases
  • Immunology
  • Genetic Diseases (includes the rare diseases)
  • Respiratory Diseases
  • Skin Diseases
  • Others (includes ophthalmic, ear diseases, etc)
• By Region
  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • South Korea
    • Rest of APAC
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America